Medicon Valley Biomedical Newsletter

CellCure A/S is a clinical stage Danish biotech company focused on the development of innovative cellular-based therapies for the treatment of cancer. The company has received Orphan-Drug status for i...

Researchers from the Danish Cancer Society might have discovered a method to enhance the immune system and to regenerate the ability to fight cancer effectively. If the technique is applicable to canc...

ACADIA Pharmaceuticals Inc. has announced publication of research in the Journal of Pharmacology and Experimental Therapeutics, JPET, showing that ACP-104, the major metabolite of clozapine, is a part...

As the first in the world, a research team from ALK-Abelló A/S has mapped the composition of the allergen that is the chief cause of the house dust mite allergy in humans. The allergen, referred to as...

In close collaboration with China's most renowned immunologist, Professor Nanzhan Zhong, ALK-Abelló A/S is opening its first allergy research centre in China. The laboratory is based at the Guangz...

BioInvent AB's Board of Directors has resolved to carry out a new share issue with preferential subscription rights for the company's shareholders. The share issue, which is secu...

DakoCytomation A/S, a world leader in cancer diagnostics, has decided to investigate the possibilities of selling its microbiology activities in order to sharpen its focus on cell-based cancer diagnos...

Gambro AB has signed an agreement with German-based Nephrogen, LLC as part of its Regenerative Medicine initiative announced earlier this year. The program will extend over a period of three years wit...

Gambro AB has received approximately USD 3.1 billion for the clinics, of which USD 1.3 billion will be distributed to the shareholders in accordance with the share redemption program. The Annual Gener...

LEO Pharma A/S and US-based Warner Chilcott have extended their co-operation to include the full LEO Pharma portfolio of present and future psoriasis treatments. Warner Chilcott is presently marketing...

The European health authorities have extended the approval for Ebixa, memantine, for the treatment of moderate Alzheimer's disease. Ebixa is already the leading drug for the treatment of se...

MediCult A/S and the Australian University of Adelaide have entered into a license agreement concerning the IGF II compound, which has shown promising effects on embryo development, pregnancy rates an...

NatImmune A/S and US-based Enzon Pharmaceuticals, Inc. have entered into a license agreement for NatImmune's lead development product, recombinant human Mannan-Binding Lectin, rhMBL, a protein the...

Novo Nordisk A/S and US-based ZymoGenetics, Inc have announced that the first patient has been dosed in a Phase I study with rFXIII (recombinant coagulation factor XIII) in patients undergoing cardiac...

At the 9th Healthcare Industry Forum in Beijing, Novo Nordisk announced plans to expand its R&D centre in Beijing, China. The expansion will double the number of employees from currently 30 to 60 ...

Novo Nordisk A/S has announced that the European Medicines Agency has granted EU marketing authorization for its new premix insulin analogues, NovoMix 50 and NovoMix 70, for the treatment of people wi...

Novozymes has discovered Plectasin, an antimicrobial peptide, AMP, that acts on bacterial infections that have developed resistance to conventional antibiotics. Plectasin is not only as effecti...